82 completed, 22 unknown, 14 recruiting, 9 active not recruiting. 47 Phase 2, 39 Phase 3, 19 Phase 4, 15 Not applicable, 8 Phase 1.
Follow incobotulinumtoxinA: new trials by email Literature Review of incobotulinumtoxinA trials Research Report on incobotulinumtoxinA
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Can Adjunctive Oral Magnesium Supplementation Prolong the Effect of Botulinum Toxin Type A in Excessive Gingival Display? Oral Magnesium Glycinate capsules, ● BoNT-A Injection Alone (Day 0) - Magnesium, Botulinum Toxin Type A | Not applicable | Enrolling by invitation | Cairo University | 26 | 2026-10-01 | 2026-10-14 |
| To Evaluate HU-045 With Moderate to Severe Glabellar Lines HU-045, Xeomin® - Glabellar Lines | Phase 3 | Recruiting | Huons Biopharma | 390 | 2026-09-03 | 2026-10-13 |
| Efficacy of Intracavernosal Xeomin With Tadalafil for Mild-Moderate Erectile Dysfunction IncobotulinumtoxinA (100 Units), Placebo, Tadalafil 20 MG - Erectile Dysfunction | Phase 2 | Not yet recruiting | Northwestern University | 30 | 2026-09-01 | 2026-08-14 |
| Clinical Evaluation of Botulinum Toxin a in the Management of Temporomandibular Myofascial Pain Botulinum Toxin Type A (BoNT-A), 0.9% Normal Saline (Placebo) - Temporomandibular Disorder | Phase 2 | Recruiting | Riphah International University | 118 | 2026-08-15 | 2026-09-29 |
| RELIEVE Study: NT 201 Intravesical Administration Using Vibe System (ViXe Combination Product) for the Treatment of Idiopathic Overactive Bladder NT 201 200U and Vibe System, NT 201 300U and Vibe System, Placebo and sham - Overactive Bladder (OAB) | Phase 2 | Recruiting | Vensica Therapeutics Ltd. | 210 | 2026-08-14 | 2026-10-16 |
| Botulinum Toxin Type A Versus Local Anesthetic Injection for Chronic Neuroma Pain After Combat-Related Amputation Botulinum Toxin Type A (BoNT-A), Local Anesthetic Solution - Chronic Pain Due to Injury, Neuroma of Lower Limb | Not applicable | Not yet recruiting | Ukrainian Society of Regional Anesthesia and Pain Therapy | 100 | 2026-05-30 | 2026-06-04 |
| Evaluation of the Analgesic Effect of Intramyometrial Botulinum Toxin Injection Via Hysteroscopy in Pelvic Pain Suggestive of Dysmenorrhea Xeomin, Placebo - Primary Dysmenorrhea, Chronic Pelvic Pain | Phase 3 | Recruiting | Nantes University Hospital | 222 | 2026-02-09 | 2026-07-13 |
| Individualised Cryoneurolysis to Treat Pain in the Context of Spasticity in the Upper and Lower Extremities Cryoneurolysis, Botulinum toxin - Centreal Neurological Condition, Acquired Brain Injury (Including Stroke) | Phase 4 | Recruiting | Oxford University Hospitals NHS Trust | 50 | 2025-12-02 | 2025-12-26 |
| A Clinical Study of Ultrasound-guided Botulinum Toxin A Into Salivary Gland for Sialorrhea After True Bulbar Palsy Ultrasound-Guided Botulinum Toxin Type A (BoNT-A) Salivary Gland Injection, Control (Normal saline) - Sialorrhea True Bulbar Palsy Medullary Injury | Not applicable | Withdrawn | houyajing | 2025-12-01 | 2026-06-24 | |
| A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in Europe (PLATINUM EU) NT 201, NT 201 Placebo - Neuromuscular Agents, Peripheral Nervous System Agents | Phase 3 | Active not recruiting | Merz Aesthetics GmbH | 300 | 2025-10-01 | 2026-09-10 |
| BOTOX Injection Technique for LUTS Due to BPH Botulinum Toxin Type A (BoNT-A) - Benign Prostatic Hyperplasia | Phase 1 | Completed | Benha University | 60 | 2025-10-01 | 2026-06-12 |
| Prospective, Non-interventional Study Assessing Periorbital Rejuvenation Procedure Letybo®, Philart® Eye, Saypha® Volume Plus Lidocaine - Glabellar Lines, Midface Volume Deficiency | Completed | Yuvell | 29 | 2025-09-02 | 2026-03-23 | |
| A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the United States NT 201, NT 201 Placebo - Neuromuscular Agents, Peripheral Nervous System Agents | Phase 3 | Active not recruiting | Merz North America, Inc. | 300 | 2025-08-27 | 2026-09-10 |
| A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine Xeomin, Placebo - Chronic Migraine | Phase 3 | Active not recruiting | Merz Therapeutics GmbH | 808 | 2025-08-21 | 2026-10-14 |
| A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine Xeomin, Placebo - Episodic Migraine | Phase 3 | Active not recruiting | Merz Therapeutics GmbH | 997 | 2025-08-21 | 2026-10-14 |
| Efficacy of Xeomin for Migraines in Patients With Traumatic Brain Injuries vs. Anomalous Health Incidents Xeomin (incobotulinumtoxinA) - Migraine, Traumatic Brain Injury | Recruiting | Uniformed Services University of the Health Sciences | 60 | 2025-08-05 | 2025-12-05 | |
| Early Botulinum Toxin for Muscle Stiffness Reduction in First-Time Stroke Patients: Improving Recovery and Independence Botulinum Toxin Type A (BoNT-A) - Spasticity, Stroke | Early Phase 1 | Active not recruiting | Instituto Mexicano del Seguro Social | 200 | 2025-01-28 | 2025-02-10 |
| Understanding and Treating Traumatic Brain Injury (TBI) Associated Photophobia With Botulinum Toxin Type A (BoNT-A) BoNT A - Traumatic Brain Injury | Phase 2 | Recruiting | University of Miami | 50 | 2024-09-30 | 2026-08-14 |
| Effects of Microtox on Facial Skin Quality, Fine Wrinkles, and Texture PrabotulinumtoxinA-Xvfs, IncobotulinumtoxinA, saline solution (placebo) - Skin Aging, Skin Wrinkling | Phase 1 | Completed | Kalpna Kay Durairaj, MD, FACS | 20 | 2024-09-03 | 2025-10-21 |
| To Evaluate HU-045 in the Treatment of Glabellar Lines(Phase III) HU-045, Xeomin® - Glabellar Lines | Phase 3 | Recruiting | Huons Biopharma | 312 | 2024-06-20 | 2024-10-03 |
Showing 20 of 140. Sign in to see all of them.
Muscle Spasticity (10) · Stroke (9) · Cerebral Palsy (6) · Brain Injuries, Traumatic (5) · Pain (5) · Torticollis (5) · Urinary Bladder, Overactive (5) · Blepharospasm (4) · Bruxism (3) · Migraine Disorders (3) · Neuralgia (3) · Parkinson Disease (3) · Tremor (3) · Chronic Pain (2) · Dystonia (2)
Merz Pharmaceuticals GmbH (31) · Merz North America, Inc. (7) · Buddhist Tzu Chi General Hospital (5) · Merz Therapeutics GmbH (4) · Allergan (3) · Merz Aesthetics GmbH (3) · Western University, Canada (3) · Yale University (3) · Assistance Publique - Hôpitaux de Paris (2) · Beth Israel Deaconess Medical Center (2) · Cairo University (2) · Huons Biopharma (2) · Northwestern University (2) · Region Västerbotten (2) · Sir Run Run Shaw Hospital (2)
United States (55) · Germany (27) · Canada (15) · France (15) · Poland (14) · Italy (10) · Russia (10) · Spain (10) · Austria (8) · Czechia (8) · United Kingdom (8) · South Korea (6) · Switzerland (6) · Ukraine (6) · Hungary (5)
Hann-Chorng Kuo, M.D. (5) · Bahman Jabbari, MD (3) · Mandar Jog, MD (2) · Alastair Carruthers, MD (1) · Anat Galor, MD/MSPH (1) · Anna S Trikhacheva, MD (1) · Antonella Giannantoni, M.D. (1) · Berthold Rzany, Prof. Dr. med Sc.M. (1)
PMID 36136523, PMID 39475143, PMID 40968493, PMID 10077661, PMID 10641699, PMID 10695888, PMID 10811692, PMID 10925088, PMID 11176403, PMID 11402097, PMID 11857671, PMID 12167681, PMID 12525714, PMID 12894267, PMID 1356988, PMID 14684785, PMID 15030944, PMID 15234492, PMID 17352514, PMID 17385940, PMID 18003941, PMID 18289791, PMID 18355307, PMID 18498422, PMID 18546285, PMID 19648387, PMID 19811515, PMID 19941278, PMID 20123097, PMID 20171668, PMID 2023770, PMID 20358216, PMID 20360543, PMID 21050394, PMID 21130559, PMID 21134045, PMID 21368663, PMID 21520284, PMID 21764407, PMID 21791356, PMID 22010053, PMID 22071153, PMID 22182409, PMID 22200394, PMID 22385408, PMID 2252363, PMID 22747635, PMID 2297305, PMID 23190342, PMID 23192713
2008 (2), 2018 (2), 2014 (1), 2017 (1), 2019 (1), 2025 (1), U01DK060817 (1)